GlassScriptPhysician profile
David Y Feigenblum
NPI 1356357420
$10,932.00
in general payments reported to CMS, 2019-2025
24 companies · $2,443 in 2025
The $2,443 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $578 · 2021: $538 · 2022: $2,320 · 2023: $949 · 2024: $3,109 · 2025: $2,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,985 · Travel and Lodging: $2,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,984.51 |
| Travel and Lodging | $2,515.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,936.04 | 2019-2025 | Aveir, Jot Dx, Assurity |
| Medtronic, INC. | $3,204.30 | 2021-2025 | Evera Mri Xt Dr Surescan, Aurora Ev-Icd Mri Surescan, Micra |
| Boston Scientific Corporation | $1,244.86 | 2019-2025 | Resonate El Icd Vr, General - Therapies, Ingevity+ |
| Medtronic Vascular, INC. | $804.65 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $323.69 | 2019-2025 | Lifevest |
| Cardiva Medical, INC. | $244.62 | 2022-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Atricure, INC. | $244.07 | 2019-2024 | |
| Biosense Webster, INC. | $165.18 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $159.42 | 2021-2024 | Optimizer |
| Philips North America LLC | $141.20 | 2022-2025 | (9274) Lld, Mcot |
| Cordis US Corp. | $98.08 | 2025 | Mynx Control Venous |
| E.R. Squibb & Sons, L.L.C. | $67.28 | 2019-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $43.83 | 2019-2020 | |
| Abiomed | $43.30 | 2024 | Impella |
| Chiesi USA, INC. | $38.98 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $37.93 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $27.61 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $24.22 | 2019 | |
| Cardiovascular Systems INC. | $15.22 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.82 | 2020 | |
| Amgen INC. | $13.89 | 2019 | |
| Amarin Pharma, INC. | $12.28 | 2019 | |
| Glaxosmithkline, LLC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Feigenblum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.